Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$419.3M
53M shares
52-week range
$4.79 – $11.58
43% from low
Sector
INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL
Exchange
NASDAQ
CS
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.
www.senseonics.comNo one on the platform currently holds SENS.
No tracked institution reports a position in SENS as of their last filing.
| Execution date | Ratio |
|---|---|
| 2025-10-20 | 1-for-20reverse |
No one on the platform has traded SENS yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
@JInvestTrade Thanks, $ELDN is definitely interesting and worth watching. But I wouldn’t call it a threat to $SENS yet. It’s still an experimental transplant + immunosuppression approach with a long road ahead. Meanwhile, $SENS has a real commercial product, Eversense 365, rapidly growing revenues and expanding integrations. Different stages, different risks. If anything, the progress in diabetes technology makes the whole space more exciting. I’m still bullish on $SENS. 👍
View on StockTwits ↗$SENS now that all the ascencia sales people that were selling eversence CGM are fully transitioned over as a $SENS employee, $SENS They don’t have to share any profit with ascencia. They are making more money now for every CGM implanted. See the interview with the CEO I previously posted.
View on StockTwits ↗$SENS We respectfully disagree. Revenue HAS been increasing. Cash burn MIGHT. Also, BlackRock
View on StockTwits ↗$SENS I know the bulls here are just being bullish about the stock they own. I respect that. But, being realistic here, the company will need to raise cash again in a few months. They don’t know when / if they will be profitable. The cash burn is increasing, and ceo said it will continue to increase. If they have to spend $40M capex for $15M revenue , the business will never work anyway. This is a speculative play , and it’s extra speculative. My opinion, this is one of the best shorts on the market right now. The hype is wearing off from earnings , and this will likely start the inevitable downtrend after every pop.
View on StockTwits ↗$SENS Waiting for this thing to skyrocket like...
View on StockTwits ↗$SENS down down down where lands no one knows I know right back where it started last month! Welcome bag holders sit down take a rest. You’re gonna be here a while.!!!
View on StockTwits ↗$SENS I’ve been able to short the morning pop like 3 days in a row. Hit some fat profit today in ONDS
View on StockTwits ↗Wait a minute... $DXCM $SENS We're coming for that sweet, sweet market share.
View on StockTwits ↗$SENS Will Abbot wait another year for the share price to increase or make their move now? This is a pocket change for them.
View on StockTwits ↗$SENS love the smell of freshly exercised 2.5cs in the morning
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $62M | +77.0% | $-2.40 | $-2.77–$-2.11 | — | 5 |
| 2027 | $98M | +57.2% | $-2.15 | $-2.73–$-1.92 | — | 5 |
| 2028 | $135M | +38.2% | $-1.57 | $-2.08–$-1.15 | — | 4 |
| 2029 | $196M | +44.9% | $-0.96 | $-1.12–$-0.89 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $-0.61 | $-0.63 | -2.8% |
| 2026-05-07 | $-0.69 | $-0.71 | -3.6% |
| 2026-03-02 | $-0.43 | $-0.46 | -7.0% |
| 2025-11-05 | $-0.33 | $-0.43 | -30.3% |
| 2025-08-06 | $-0.40 | $-0.40 | +0.0% |
| 2025-05-08 | $-0.40 | $-0.40 | +0.0% |
| 2025-03-03 | $-0.03 | $-0.40 | -1233.3% |
| 2024-11-07 | $-0.60 |
| $-0.80 |
| -33.3% |
| $78M |
| — |
| MASS908 Devices Inc. | $10.11 | +0.90% | $415M | — |
| NNOXNano-X Imaging Ltd. | $0.98 | -3.43% | $69M | — |
Source: Financial Modeling Prep · peers by sector/industry